Good morning :)
$
₹
Kymera Therapeutics Inc

Kymera Therapeutics Inc

KYMR

NASDAQ
Asset Logo

Kymera Therapeutics Inc

KYMR

NASDAQ
$136.227.19% (+9.13)
$
₹
$136.227.19% (+9.13)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $10.9B the stock is ranked 914

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

6.70
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-3.64
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 24 analysts reports

Buy
22 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+13.61%

Earnings Growth

-5.44%

Rev. Growth

+153.6%

See Detailed Forecast

Company Profile

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 13.61% growth, versus a trailing 3-year CAGR of 107.28%.

2026
Current$127.09Baseline
Analyst Target - 1 year
Target$144.39+13.61%

All values in $

202220232024202520262027$56.56$90.65$124.74Target+13.61%
2026
Current$127.09Baseline
Analyst Target - 1 year
Target$144.39+13.61%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 153.60% growth, versus a trailing 3-year CAGR of -5.75%.

2025
Current$39.2Baseline
Forecast for Dec 2026
High$101.4+158.67%
Average$99.41+153.6%
Low$98+150%

All values in $ Million

20212022202320242025202672.8346.8278.5947.0739.2Low+150%Average+153.6%High+158.67%
2025
Current$39.2Baseline
Forecast for Dec 2026
High$101.4+158.67%
Average$99.41+153.6%
Low$98+150%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.68Baseline
Forecast for Dec 2026
High$-3.13+14.95%
Average$-3.88-5.44%
Low$-4.21-14.4%

All values in $

202120222023202420252026-2.06-2.88-2.52-2.91-3.68Low-14.4%Average-5.44%High+14.95%
2025
Current$-3.68Baseline
Forecast for Dec 2026
High$-3.13+14.95%
Average$-3.88-5.44%
Low$-4.21-14.4%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2.8
-87
34.3
-69.2
65
-61.2
-131.9
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue25.653.747.3922.111.472.762.8634.36650
Net Income-42.06-62.48-70.75-65.58-76.61-82.17-87.03-69.23-61.21-131.99
Net Profit Margin-163.98%-1670.32%-956.88%-296.74%-667.60%-2973.04%-3043.00%-201.46%-94.17%-
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Kymera Therapeutics Inc -6.70-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare KYMR with any stock or ETF
Compare KYMR with any stock or ETF
Comparing from
KYMR
ABBV
AMGN
Loading...

Frequently asked questions

  1. Kymera Therapeutics Inc (KYMR) share price today is $136.22 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $136.30 and a day low of $126.20.

  2. Kymera Therapeutics Inc stock trades on NASDAQ under the ticker symbol KYMR.

  3. Kymera Therapeutics Inc's market capitalization is $10.88B as of November 5, 2026 at 2:29 AM IST.

  4. Kymera Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Kymera Therapeutics Inc's price-to-book (P/B) ratio is 6.70 as of November 4, 2026.

  6. Yes, You can buy Kymera Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Kymera Therapeutics Inc shares in three steps: 1. Search Kymera Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Kymera Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Kymera Therapeutics Inc (KYMR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0734 shares at the current price of $136.22.

Loading...